Search

Your search keyword '"F. Baskaya"' showing total 2 results
Start Over Author "F. Baskaya" Publisher springer
2 results on '"F. Baskaya"'

1. Assessment of Chemotherapy-Induced Organ Damage with Ga-68 Labeled Duramycin

Author

Anne Rix, Anna Mrugalla, Natascha Drude, E. Fiegle, Fabian Kiessling, Brian D. Gray, Koon Y. Pak, Felix M. Mottaghy, Wiltrud Lederle, Rene Tolba, H.-J. Kaiser, F. Baskaya, Beeldvorming, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
Cancer Research, Pathology, medicine.medical_specialty, medicine.medical_treatment, Apoptosis, THERAPY, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, CISPLATIN, 0302 clinical medicine, In vivo, medicine, Chemotherapy, Radiology, Nuclear Medicine and imaging, Doxorubicin, Duramycin, PRECLINICAL EVALUATION, PET-CT, medicine.diagnostic_test, Toxicity, business.industry, MOLECULAR-MECHANISMS, MICE, PET, Oncology, Positron emission tomography, Immunohistochemistry, business, Busulfan, medicine.drug, CT
Abstract

PURPOSE: Evaluation of [68Ga]NODAGA-duramycin as a positron emission tomography (PET) tracer of cell death for whole-body detection of chemotherapy-induced organ toxicity.PROCEDURES: Tracer specificity of Ga-68 labeled NODAGA-duramycin was determined in vitro using competitive binding experiments. Organ uptake was analyzed in untreated and doxorubicin, busulfan, and cisplatin-treated mice 2 h after intravenous injection of [68Ga]NODAGA-duramycin. In vivo data were validated by immunohistology and blood parameters.RESULTS: In vitro experiments confirmed specific binding of [68Ga]NODAGA-duramycin. Organ toxicities were detected successfully using [68Ga]NODAGA-duramycin PET/X-ray computed tomography (CT) and confirmed by immunohistochemistry and blood parameter analysis. Organ toxicities in livers and kidneys showed similar trends in PET/CT and immunohistology. Busulfan and cisplatin-related organ toxicities in heart, liver, and lungs were detected earlier by PET/CT than by blood parameters and immunohistology.CONCLUSION: [68Ga]NODAGA-duramycin PET/CT was successfully applied to non-invasively detect chemotherapy-induced organ toxicity with high sensitivity in mice. It, therefore, represents a promising alternative to standard toxicological analyses with a high translational potential.

Published
2020

2. Assessment of Chemotherapy-Induced Organ Damage with Ga-68 Labeled Duramycin.

Author

Rix A, Drude NI, Mrugalla A, Baskaya F, Pak KY, Gray B, Kaiser HJ, Tolba RH, Fiegle E, Lederle W, Mottaghy FM, and Kiessling F

Subjects
Acetates chemistry, Acetates metabolism, Animals, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Busulfan administration & dosage, Cisplatin administration & dosage, Doxorubicin administration & dosage, Female, Heterocyclic Compounds, 1-Ring chemistry, Heterocyclic Compounds, 1-Ring metabolism, Kidney metabolism, Kidney pathology, Liver metabolism, Liver pathology, Mice, Mice, Inbred BALB C, Neoplasms pathology, Positron Emission Tomography Computed Tomography methods, Radiopharmaceuticals chemistry, Radiopharmaceuticals pharmacokinetics, Tissue Distribution, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bacteriocins chemistry, Bacteriocins pharmacokinetics, Gallium Radioisotopes chemistry, Gallium Radioisotopes pharmacokinetics, Kidney diagnostic imaging, Kidney drug effects, Liver diagnostic imaging, Liver drug effects, Neoplasms drug therapy, Peptides chemistry, Peptides pharmacokinetics
Abstract

Purpose: Evaluation of [ 68 Ga]NODAGA-duramycin as a positron emission tomography (PET) tracer of cell death for whole-body detection of chemotherapy-induced organ toxicity., Procedures: Tracer specificity of Ga-68 labeled NODAGA-duramycin was determined in vitro using competitive binding experiments. Organ uptake was analyzed in untreated and doxorubicin, busulfan, and cisplatin-treated mice 2 h after intravenous injection of [ 68 Ga]NODAGA-duramycin. In vivo data were validated by immunohistology and blood parameters., Results: In vitro experiments confirmed specific binding of [ 68 Ga]NODAGA-duramycin. Organ toxicities were detected successfully using [ 68 Ga]NODAGA-duramycin PET/X-ray computed tomography (CT) and confirmed by immunohistochemistry and blood parameter analysis. Organ toxicities in livers and kidneys showed similar trends in PET/CT and immunohistology. Busulfan and cisplatin-related organ toxicities in heart, liver, and lungs were detected earlier by PET/CT than by blood parameters and immunohistology., Conclusion: [ 68 Ga]NODAGA-duramycin PET/CT was successfully applied to non-invasively detect chemotherapy-induced organ toxicity with high sensitivity in mice. It, therefore, represents a promising alternative to standard toxicological analyses with a high translational potential.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results